The Centers for Medicare and Medicaid Services has proposed that payment for CT colonography be declined, saying there is not enough evidence to support it as a colorectal cancer screening tool.
The Centers for Medicare and Medicaid Services has proposed that payment for CT colonography be declined, saying there is not enough evidence to support it as a colorectal cancer screening tool.
In a Proposed Decision Memorandum issued Feb. 11, CMS suggests that existing scientific evidence is inadequate to conclude that CTC improves net health benefits for asymptomatic, average risk Medicare beneficiaries. CMS thus decided that CTC for colorectal cancer screening should remain uncovered.
"While it is a promising technology, many questions on the use of CT colonography need to be answered with well-designed clinical studies that focus on health outcomes for the Medicare population. Until the evidence is sufficient, CMS strongly encourages physicians and beneficiaries to participate in colorectal cancer screening by selecting one of the several CRC screening tests that are currently covered under Medicare," CMS said in its memo.
CMS requested public feedback on the proposed determination and announced it will issue a final decision after considering comments. In its statement, however, CMS cautioned that even if it finds that CTC is clinically effective, additional information and public comments would be needed to determine the test cost effectiveness.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.
Systematic Review: PET/MRI May be More Advantageous than PET/CT in Cancer Imaging
July 18th 2024While PET/MRI and PET/CT had comparable sensitivity for patient-level regional nodal metastases and lesion-level recurrence, the authors of a systematic review noted that PET/MRI had significantly higher accuracy in breast cancer and colorectal cancer staging.
FDA Clears Enhanced Mobile CT System with High-Resolution Photon-Counting Technology
July 15th 2024Photon-counting CT-optimized features with the OmniTom Elite system include 30 cm field of view scanning, continuous spiral scanning, and an ultra-high-resolution capability of 0.141 mm resolution.